Rasna Therapeutics, Inc. (RASP)
USD 0.0
(900.0%)
USD 0.0
(900.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 4.23 Million USD | -1.12% |
| 2022 | 383.91 Thousand USD | 54.92% |
| 2021 | 247.81 Thousand USD | -55.47% |
| 2020 | 556.5 Thousand USD | -39.19% |
| 2019 | 915.17 Thousand USD | -77.52% |
| 2018 | 4.07 Million USD | -10.24% |
| 2017 | 4.53 Million USD | 7187.07% |
| 2016 | 62.22 Thousand USD | 271.35% |
| 2015 | 16.75 Thousand USD | -58.14% |
| 2014 | 40.03 Thousand USD | 646.92% |
| 2013 | 5360.00 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 71.38 Thousand USD | -42.77% |
| 2024 Q1 | 124.73 Thousand USD | 155.46% |
| 2023 Q2 | 3.96 Million USD | 3129.69% |
| 2023 Q4 | 48.82 Thousand USD | -51.33% |
| 2023 Q1 | 122.81 Thousand USD | 296.22% |
| 2023 FY | 379.62 Thousand USD | -1.12% |
| 2023 Q3 | 100.32 Thousand USD | -97.47% |
| 2022 Q1 | 81.79 Thousand USD | 225.21% |
| 2022 Q4 | 30.99 Thousand USD | -75.76% |
| 2022 Q2 | 143.26 Thousand USD | 75.16% |
| 2022 FY | 383.91 Thousand USD | 54.92% |
| 2022 Q3 | 127.86 Thousand USD | -10.75% |
| 2021 Q4 | -65.32 Thousand USD | -201.16% |
| 2021 FY | 247.81 Thousand USD | -55.47% |
| 2021 Q1 | 154.94 Thousand USD | 16.43% |
| 2021 Q3 | 64.57 Thousand USD | -31.03% |
| 2021 Q2 | 93.62 Thousand USD | -39.58% |
| 2020 Q1 | 149.28 Thousand USD | 145.9% |
| 2020 Q4 | 133.07 Thousand USD | 43.77% |
| 2020 Q3 | 92.56 Thousand USD | -49.02% |
| 2020 Q2 | 181.58 Thousand USD | 21.64% |
| 2020 FY | 556.5 Thousand USD | -39.19% |
| 2019 Q2 | 263.29 Thousand USD | -34.07% |
| 2019 Q4 | 60.7 Thousand USD | -68.36% |
| 2019 FY | 915.17 Thousand USD | -77.52% |
| 2019 Q3 | 191.84 Thousand USD | -27.14% |
| 2019 Q1 | 399.32 Thousand USD | -1.47% |
| 2018 Q3 | 809.38 Thousand USD | -28.8% |
| 2018 Q2 | 1.13 Million USD | -43.16% |
| 2018 Q1 | 1.99 Million USD | 9.93% |
| 2018 FY | 4.07 Million USD | -10.24% |
| 2018 Q4 | 405.28 Thousand USD | -49.93% |
| 2017 Q1 | 1.37 Million USD | 2.67% |
| 2017 Q2 | 990.2 Thousand USD | -28.12% |
| 2017 Q4 | 1.81 Million USD | 47.86% |
| 2017 Q3 | 1.23 Million USD | 24.25% |
| 2017 FY | 4.53 Million USD | 7187.07% |
| 2016 Q3 | 55.19 Thousand USD | 2929.58% |
| 2016 Q4 | 1.34 Million USD | 2330.71% |
| 2016 Q2 | 1822.00 USD | -56.94% |
| 2016 FY | 62.22 Thousand USD | 271.35% |
| 2016 Q1 | 4231.00 USD | 333.95% |
| 2015 Q1 | 3672.00 USD | 7.06% |
| 2015 FY | 16.75 Thousand USD | -58.14% |
| 2015 Q4 | 975.00 USD | -68.51% |
| 2015 Q2 | 6559.00 USD | 78.62% |
| 2015 Q3 | 3096.00 USD | -52.8% |
| 2014 FY | 40.03 Thousand USD | 646.92% |
| 2014 Q1 | 14.21 Thousand USD | 90.5% |
| 2014 Q2 | 3491.00 USD | -75.44% |
| 2014 Q3 | 14.86 Thousand USD | 325.78% |
| 2014 Q4 | 3430.00 USD | -76.92% |
| 2013 FY | 5360.00 USD | 0.0% |
| 2013 Q2 | 4305.00 USD | 0.0% |
| 2013 Q4 | 7463.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -217.382% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 15.939% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 85.658% |
| Nascent Biotech, Inc. | 2.22 Million USD | -90.074% |
| Rebus Holdings, Inc. | 664 Thousand USD | -538.315% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 88.623% |
| Qrons Inc. | 643.67 Thousand USD | -558.469% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -987.984% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 92.621% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -920.127% |
| Skye Bioscience, Inc. | 13.54 Million USD | 68.715% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 95.116% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 13.817% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -1519.409% |
| SQZ Biotechnologies Company | 85.61 Million USD | 95.05% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -45.339% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -182.204% |
| Mesoblast Limited | 5.9 Million USD | 28.187% |
| Marizyme, Inc. | 19.23 Million USD | 77.971% |
| Genus plc | 147.7 Million USD | 97.13% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 51.722% |
| Pharming Group N.V. | 225.49 Million USD | 98.12% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -106.883% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -215.935% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 49.174% |
| ContraFect Corporation | 56.88 Million USD | 92.55% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 3.862% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -186.621% |
| IMV Inc. | 37.7 Million USD | 88.76% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -51.895% |
| MultiCell Technologies, Inc. | 567.42 USD | -746862.391% |
| ONE Bio Corp. | 6.44 Million USD | 34.226% |
| Accustem Sciences Inc. | 3.74 Million USD | -13.132% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 95.068% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -696.751% |
| Q BioMed Inc. | 3.43 Million USD | -23.331% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 82.851% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -61.308% |
| Biomind Labs Inc. | 994.18 Thousand USD | -326.322% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 95.733% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -140.863% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 36.91% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -127.338% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 17053.656% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 73.527% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -130.964% |
| GB Sciences, Inc. | 1.42 Million USD | -198.373% |
| Alpha Cognition Inc. | 9.7 Million USD | 56.33% |
| HST Global, Inc. | 140.9 Thousand USD | -2907.951% |
| CSL Limited | 3.44 Billion USD | 99.877% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -276.778% |
| Halberd Corporation | 74.84 Thousand USD | -5563.149% |
| Enzolytics Inc. | 2.17 Million USD | -94.467% |
| Agentix Corp. | 1.37 Million USD | -208.977% |
| Resverlogix Corp. | 12.71 Million USD | 66.658% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -16.098% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.724% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -305.978% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -76.238% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -168.364% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -24.477% |
| AVAX Technologies, Inc. | 7.31 Million USD | 42.021% |
| Zenith Capital Corp. | 8.94 Million USD | 52.606% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.486% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -24229.338% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -72.622% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -2371.249% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -120.647% |
| Kadimastem Ltd | 2.41 Million USD | -75.86% |
| Helix BioMedix, Inc. | 1.97 Million USD | -114.926% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 60.997% |
| BioStem Technologies, Inc. | 22.97 Million USD | 81.552% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -2235.407% |
| LadRx Corporation | 3.81 Million USD | -11.192% |
| Cell Source, Inc. | 4.32 Million USD | 2.01% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -358.946% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -358.946% |
| NovAccess Global Inc. | 2.46 Million USD | -71.821% |
| Affymax, Inc. | 39.38 Million USD | 89.239% |
| Itoco Inc. | 919.14 Thousand USD | -361.127% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -278.768% |
| Mobile Lads Corp. | 554.54 Thousand USD | -664.303% |
| CytoDyn Inc. | 18.05 Million USD | 76.529% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -16739.819% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -1825.869% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -198.524% |
| SYBLEU INC | 160.87 Thousand USD | -2534.584% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -133.352% |
| International Stem Cell Corporation | 5.27 Million USD | 19.59% |
| Bioxytran, Inc. | 3.82 Million USD | -10.949% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -7951.392% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -20734.754% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 88.313% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -161.954% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -476.001% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -36.24% |
| Neutra Corp. | 243.82 Thousand USD | -1638.33% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 75.721% |
| PureTech Health plc | 144.59 Million USD | 97.069% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 79.315% |
| IXICO plc | 4.7 Million USD | 9.955% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 51.82% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 96.4% |
| CSL Limited | 3.89 Billion USD | 99.891% |
| Cellectis S.A. | 97.32 Million USD | 95.645% |